Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Last Updated: March 21, 2023

Details for Patent: 8,118,802

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,118,802 protect, and when does it expire?

Patent 8,118,802 protects NAROPIN and is included in one NDA.

This patent has twenty-eight patent family members in twenty countries.

Summary for Patent: 8,118,802

Title:	Connector for packaging containing medical fluids and packaging for medical fluids
Abstract:	The disclosure relates to a connector for packaging containing medical fluids, in particular infusion or transfusion bags, including a tubular connection part for receiving a spike for the withdrawal of fluid, and having a lower opening on the packaging side and an upper opening on the connection side. A self-sealing membrane, which is pierced by the spike, is located in the connection part. The membrane has an upper, annular section leading into a lower, plate-shaped section, said annular section of the membrane surrounding the spike in a sealing manner, when the latter pierces the plate-shaped section. The membrane acts as a guide for the spike and also reseals the connector, once the spike has been removed.
Inventor(s):	Brandenburger; Torsten (Niddatal, DE), Rahimy; Ismael (Friedberg, DE)
Assignee:	Fresenius Kabi Deutschland GmbH (Bad Homburg, DE)
Application Number:	12/858,627
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,118,802
Patent Claim Types: see list of patent claims

Drugs Protected by US Patent 8,118,802

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Fresenius Kabi Usa	NAROPIN	ropivacaine hydrochloride	SOLUTION;INJECTION	020533-006	Sep 24, 1996	AP	RX	Yes	No	See Plans and Pricing	See Plans and Pricing	Y				See Plans and Pricing
Fresenius Kabi Usa	NAROPIN	ropivacaine hydrochloride	SOLUTION;INJECTION	020533-007	Sep 24, 1996	AP	RX	Yes	No	See Plans and Pricing	See Plans and Pricing	Y				See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 8,118,802

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	102 23 560	May 27, 2002

International Family Members for US Patent 8,118,802

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	469630	See Plans and Pricing
Australia	2003208752	See Plans and Pricing
Brazil	0311342	See Plans and Pricing
Brazil	PI0311342	See Plans and Pricing
Canada	2487551	See Plans and Pricing
China	100398084	See Plans and Pricing
China	1655750	See Plans and Pricing
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca

Moodys

Baxter

McKesson

Merck

Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.